These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38126951)

  • 1. Risk of HCC decreases in HBV-related patients with cirrhosis acquired recompensation: A retrospective study based on Baveno VII criteria.
    Zhang Y; Liu X; Li S; Lin C; Ye Q; Wang Y; Wu J; Zhang Y; Gao H; Li T; Qu Y; Wang Y
    Hepatol Commun; 2024 Jan; 8(1):. PubMed ID: 38126951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baveno VII criteria for recompensation predict transplant-free survival in patients with hepatitis B-related decompensated cirrhosis.
    Hui VW; Wong GL; Wong VW; Chan HL; Lai JC; Tse YK; Lai MS; Yam TF; Li D; Fan X; Yip TC
    JHEP Rep; 2023 Sep; 5(9):100814. PubMed ID: 37546279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of Baveno VII criteria for recompensation in entecavir-treated patients with hepatitis B-related decompensated cirrhosis.
    Wang Q; Zhao H; Deng Y; Zheng H; Xiang H; Nan Y; Hu J; Meng Q; Xu X; Fang J; Xu J; Wang X; You H; Pan CQ; Xie W; Jia J
    J Hepatol; 2022 Dec; 77(6):1564-1572. PubMed ID: 36038017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recompensation in treatment-naïve HBV-related decompensated cirrhosis: a 5-year multi-center observational study comparing patients with ascites and bleeding.
    He Z; Wang B; Wu X; Hu Z; Zhang C; Hao Y; Yang Y; Huang Y; Rao W; Wang J; Zhou J; Xia S; Ou X; Jia J; You H
    Hepatol Int; 2023 Dec; 17(6):1368-1377. PubMed ID: 37775724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
    Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
    J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recompensation after TIPS reduces the incidence of hepatocellular carcinoma and increases survival in patients with cirrhosis.
    Sánchez J; González S; Poyatos P; Escudero MD; Montón C; Carbonell JA; Casula E; Guijarro J; Lluch P; Ballester MP
    Liver Int; 2024 Nov; 44(11):3072-3082. PubMed ID: 39221765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcomes of patients with hepatitis B virus-related acute on chronic liver failure: An observational cohort study.
    Lin S; Zhang K; Zhang J; Wang M; Velani B; Zhu Y
    Liver Int; 2019 May; 39(5):854-860. PubMed ID: 30753752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
    Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
    J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Baveno VII concept of cirrhosis recompensation.
    Reiberger T; Hofer BS
    Dig Liver Dis; 2023 Apr; 55(4):431-441. PubMed ID: 36646527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new model predicts hepatocellular carcinoma in patients with HBV-related decompensated liver cirrhosis and long-term antiviral therapy: a prospective study.
    Mao HD; Zheng SQ; Yang SH; Huang ZY; Xue Y; Zhou M
    PeerJ; 2023; 11():e15014. PubMed ID: 36992940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spleen-dedicated stiffness measurement performed well to rule out high-risk varices in HBV-related hepatocellular carcinoma: Screening for high-risk varices in HCC.
    Cheng X; Tang Y; He Q; Song J; Wang K; Li H; Huang J; Wang W; Li J; Wang H; Tu M; Chen J; Yuan G; Kang S; Liu H; Zhang X; Luo W; Ji Y; Lan X; Zhou L; Lai Q; Luo X; Wu Q; Zhou D; Tan Y; Chen J; Zhang X
    Aliment Pharmacol Ther; 2024 Mar; 59(5):680-691. PubMed ID: 38155565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
    Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
    Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recompensation of complications in patients with hepatitis B virus-related decompensated cirrhosis treated with entecavir antiviral therapy].
    Zhang T; Deng Y; Kang HY; Xiang HL; Nan YM; Hu JH; Meng QH; Fang JL; Xu J; Wang XM; Zhao H; Pan CQ; Jia JD; Xu XY; Xie W
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jul; 31(7):692-697. PubMed ID: 37580250
    [No Abstract]   [Full Text] [Related]  

  • 15. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol-related cirrhosis.
    Hofer BS; Simbrunner B; Hartl L; Jachs M; Balcar L; Paternostro R; Schwabl P; Semmler G; Scheiner B; Trauner M; Mandorfer M; Reiberger T
    Liver Int; 2023 Oct; 43(10):2220-2231. PubMed ID: 37469291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program.
    Premkumar M; Dhiman RK; Duseja A; Mehtani R; Taneja S; Gupta E; Gupta P; Sandhu A; Sharma P; Rathi S; Verma N; Kulkarni AV; Bhujade H; Chaluvashetty SB; Kalra N; Grover GS; Nain J; Reddy KR
    Gastroenterology; 2024 Dec; 167(7):1429-1445. PubMed ID: 39181168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
    Kumada T; Toyoda H; Yasuda S; Miyake N; Ito T; Tanaka J
    J Viral Hepat; 2021 Mar; 28(3):508-516. PubMed ID: 33306854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study.
    Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ
    World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.